Dasatinib Tops Imatinib for Ph + Acute Lymphoblastic Leukemia
Four - year cumulative risk of any relapse lower for dasatinib in the context of intensive chemotherapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 21, 2020 Category: Cancer & Oncology Tags: Oncology, Pathology, Pediatrics, Pharmacy, Journal, Source Type: news
Dasatinib Tops Imatinib for Ph & #43; Acute Lymphoblastic Leukemia
TUESDAY, Jan. 21, 2020 -- Dasatinib is associated with improved survival for pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), according to a study published online Jan. 16 in JAMA Oncology.
Shuhong Shen,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 21, 2020 Category: Pharmaceuticals Source Type: news
Defining the Landscape of Mutations Present in Pediatric Acute Lymphoblastic Leukemia
This research has the potential to aid in the development of new strategies for early detection of relapse in pediatric patients with ALL, and the development of treatments to counter clinical occurrence. (Source: CancerNetwork)
Source: CancerNetwork - January 20, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Acute leukemia patients treated with common therapy have increased risk for heart failure
(University of Pennsylvania School of Medicine) Patients with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) who are treated with anthracyclines are at a heightened risk of heart failure -- most often within one year of exposure to the chemotherapy treatment, according to a new study led by researchers at Penn Medicine. To help identify a patient's risk for heart failure following the treatment, researchers developed a risk score (0 to 21) based on clinical and echographic variables. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 17, 2019 Category: Cancer & Oncology Source Type: news
Immunotherapy drug improves outcomes for some children with relapsed leukemia
Blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia that has relapsed. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - December 10, 2019 Category: American Health Source Type: news
Immunotherapy drug improves outcomes for some children with relapsed leukemia
(NIH/National Cancer Institute) New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia (B-ALL) that has relapsed. Those treated with blinatumomab had longer survival, experienced fewer severe side effects, had a higher rate of undetectable residual disease, and were more likely to proceed to a stem cell transplant. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 10, 2019 Category: Cancer & Oncology Source Type: news
New approach to treating incurable leukemia in children discovered
(University of Zurich) Acute lymphoblastic leukemia is the most common form of cancer affecting children in Switzerland and, unfortunately, is often incurable. Researchers from the University of Zurich and the University Children's Hospital Zurich have now found a way to stop the driving force behind this type of leukemia at a molecular level and develop a targeted therapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 25, 2019 Category: Cancer & Oncology Source Type: news
Prophylactic Cranial Irradiation May Not Be Needed in Children With ALL Prophylactic Cranial Irradiation May Not Be Needed in Children With ALL
In children with acute lymphoblastic leukemia (ALL) at risk for central nervous system (CNS) relapse, a higher dose of chemotherapy plus two extra doses of intrathecal therapy during early induction can obviate the need for prophylactic cranial irradiation, researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 12, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Extension of the Notch intracellular domain ankyrin repeat stack by NRARP promotes feedback inhibition of Notch signaling
Canonical Notch signaling relies on regulated proteolysis of the receptor Notch to generate a nuclear effector that induces the transcription of Notch-responsive genes. In higher organisms, one Notch-responsive gene that is activated in many different cell types encodes the Notch-regulated ankyrin repeat protein (NRARP), which acts as a negative feedback regulator of Notch responses. Here, we showed that NRARP inhibited the growth of Notch-dependent T cell acute lymphoblastic leukemia (T-ALL) cell lines and bound directly to the core Notch transcriptional activation complex (NTC), requiring both the transcription factor RB...
Source: Signal Transduction Knowledge Environment - November 4, 2019 Category: Science Authors: Jarrett, S. M., Seegar, T. C. M., Andrews, M., Adelmant, G., Marto, J. A., Aster, J. C., Blacklow, S. C. Tags: STKE Research Articles Source Type: news
Exercise Intolerance May Harm Neurocognition in ALL Survivors
MONDAY, Oct. 21, 2019 -- For adult survivors of childhood acute lymphoblastic leukemia (ALL), exercise intolerance is associated with worse neurocognitive outcomes, according to a study published online Oct. 21 in Cancer.
Nicholas S. Phillips, M.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 21, 2019 Category: Pharmaceuticals Source Type: news
Can More Exercise Improve Thinking Skills in Cancer Survivors?
MONDAY, Oct. 21, 2019 -- Boosting exercise capacity may protect the mental functioning of childhood leukemia survivors, according to a new study.
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Due to their disease and... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 21, 2019 Category: General Medicine Source Type: news
Invasive Pulmonary Aspergillosis in Acute Leukemia in the Era of New Antifungal Treatment and Prophylaxis Is Still Frequent, Even in Patients with Acute Lymphoblastic Leukemia, and Adversely Affects the Overall Treatment Outcome. Results of a 5-Year Study
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 6, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news
The Incidence of Invasive Fungal Infections in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukaemia/Lymphoma Treated with the UKALL2011 Protocol: a Multicentre Retrospective Study
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 6, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news
Cancer sufferer, five, who has always wanted to be a tattoo artist lives out her dream
The five-year-old girl, known only as Maja, is battling acute lymphoblastic leukaemia. She visited a local tattoo parlour in Cleveland, Ohio, where she was shown all the tools. (Source: the Mail online | Health)
Source: the Mail online | Health - September 27, 2019 Category: Consumer Health News Source Type: news
Amgen announces positive results from two Phase 3 BLINCYTO ® (blinatumomab) studies In pediatric patients with relapsed acute lymphoblastic leukemia
Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (20120215) showed that the primary endpoint of event-free survival was met. The study evaluated the efficacy, safety and tolerability of BLINCYTO® (blinatumomab) compared to conventional consolidation chemotherapy in pediatric patients with (Source: World Pharma News)
Source: World Pharma News - September 25, 2019 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news
